Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2020
- IND application to the FDA for the Phase I/IIa clinical trial of HDP-101 in preparation
- Private placement with gross proceeds of EUR 14.4 million and further financing commitment of EUR 15 million by majority shareholder dievini received
- Expansion of own ATAC pipeline leads to increased expenses and adjustment of forecast
- Milestone payment received from partner Magenta in September
- Encouraging first data from partner RedHill with upamostat in COVID-19
Heidelberg Pharma AG today reported on the first nine months of fiscal year 2020 (1 December 2019 – 31 August 2020) and the Group’s financial figures.